About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

IART Q2 2025 Deep Dive: Operational Transformation and Supply Recovery Shape Outlook

IART Cover Image

Medical device company Integra LifeSciences (NASDAQ: IART) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $415.6 million. The company expects next quarter’s revenue to be around $415 million, close to analysts’ estimates. Its non-GAAP profit of $0.45 per share was 4.4% above analysts’ consensus estimates.

Is now the time to buy IART? Find out in our full research report (it’s free).

Integra LifeSciences (IART) Q2 CY2025 Highlights:

  • Revenue: $415.6 million vs analyst estimates of $395 million (flat year on year, 5.2% beat)
  • Adjusted EPS: $0.45 vs analyst estimates of $0.43 (4.4% beat)
  • Adjusted EBITDA: $71.22 million vs analyst estimates of $66.75 million (17.1% margin, 6.7% beat)
  • The company dropped its revenue guidance for the full year to $1.67 billion at the midpoint from $1.68 billion, a 0.9% decrease
  • Management reiterated its full-year Adjusted EPS guidance of $2.24 at the midpoint
  • Operating Margin: 7.9%, down from 11.3% in the same quarter last year
  • Organic Revenue fell 1.4% year on year vs analyst estimates of 6.5% declines (506.3 basis point beat)
  • Market Capitalization: $1.07 billion

StockStory’s Take

Integra LifeSciences’ second quarter results reflected steady execution amid ongoing operational transformation efforts. Management attributed performance to meaningful progress on its Compliance Master Plan and remediation actions, as well as strong demand for key products like Integra Skin. CEO Mojdeh Poul highlighted, “We completed assessments at all of our internal manufacturing sites ahead of schedule, with no new shipholds identified.” The company’s operational focus and improved production output helped counteract the headwinds from supply disruptions and ongoing remediation costs.

Looking ahead, Integra LifeSciences’ updated outlook is shaped by anticipated supply recovery and continued cost discipline. Management emphasized that the company aims to restore manufacturing reliability and reintroduce products such as PriMatrix and SurgiMend, while maintaining investments in product evidence and quality systems. CFO Lea Knight outlined that guidance assumes no new material shipholds for the remainder of the year, with Poul stating, “We are laying the foundation for sustainable growth and profitability through strategic investments and disciplined cost management.”

Key Insights from Management’s Remarks

Management cited the successful completion of manufacturing site assessments, robust Integra Skin production, and ongoing cost structure optimization as the most impactful drivers this quarter.

  • Compliance Master Plan progress: The company finished all internal manufacturing site assessments ahead of schedule, which management views as a milestone for risk reduction and operational readiness. No new shipholds—temporary holds on product shipments due to compliance issues—were identified, supporting improved visibility for the rest of the year.
  • Operational improvements at Braintree: Efforts to bring the Braintree facility back online are on track, with equipment installation, staff transitions, and quality management system implementation progressing. This site is critical for the relaunch of SurgiMend and PriMatrix products, which are expected to resume production in 2026.
  • Integra Skin production recovery: Manufacturing enhancements enabled record-high Integra Skin production, allowing the business to rebuild safety stocks and meet ongoing demand. Management expects this to stabilize the wound reconstruction portfolio’s revenue contribution.
  • ENT segment integration and headwinds: The integration of Acclarent expanded the company’s ear, nose, and throat (ENT) business, but market pressure on Sinuplasty Balloons and capital sales timing impacted near-term growth. However, sub-segments like Eustachian Tube Balloon Dilation and TruDi disposables saw double-digit growth.
  • Cost structure optimization initiative: A new transformation office is driving efforts to remove redundant costs, aiming for $25–30 million in annualized savings over 12–18 months. This is intended to offset remediation costs and counteract margin pressures from tariffs and macroeconomic uncertainty.

Drivers of Future Performance

Integra LifeSciences’ near-term outlook is driven by supply recovery, continued operational improvements, and a focus on margin stabilization despite external headwinds.

  • Supply chain and product relaunch: Management expects the resumption of previously held products, particularly Integra Skin and, in the longer term, PriMatrix and SurgiMend, to drive revenue recovery. The ability to win back customers for these products is seen as achievable but will require ongoing investment and commercial focus.
  • Margin stabilization and cost controls: The company is pursuing cost savings through operational efficiency and overhead reduction. While remediation and tariff-related pressures remain headwinds, management anticipates these initiatives will help balance margin impacts and support profitability.
  • Regulatory and reimbursement changes: Proposed Medicare reimbursement adjustments for wound care are expected to favor products with strong clinical evidence and cost-effectiveness. Management is positioning the portfolio to benefit from these policy shifts over time, particularly in wound reconstruction.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace and effectiveness of product relaunches for PriMatrix and SurgiMend, (2) improvements in supply chain reliability and inventory rebuilds, and (3) the ongoing impact of cost reduction initiatives on operating margins. Regulatory developments in reimbursement policy and the ability to recapture lost customers will also be important signposts.

Integra LifeSciences currently trades at $13.77, up from $12.37 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.